

Article (refereed) - postprint

Booker, Victoria; Halsall, Crispin; Llewellyn, Neville; Johnson, Andrew; Williams, Richard. 2014. **Prioritising anticancer drugs for environmental monitoring and risk assessment purposes.** *Science of the Total Environment*, 473-474. 159-170.
<https://doi.org/10.1016/j.scitotenv.2013.11.145>

© 2013 Elsevier B.V.

This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>



This version available <http://nora.nerc.ac.uk/id/eprint/504428/>

NERC has developed NORA to enable users to access research outputs wholly or partially funded by NERC. Copyright and other rights for material on this site are retained by the rights owners. Users should read the terms and conditions of use of this material at <http://nora.nerc.ac.uk/policies.html#access>

NOTICE: this is the author's version of a work that was accepted for publication in *Science of the Total Environment*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Science of the Total Environment*, 473-474. 159-170.
<https://doi.org/10.1016/j.scitotenv.2013.11.145>

Contact CEH NORA team at
noraceh@ceh.ac.uk

Supplementary Tables and Figures

Table S1: Use/consumption data of anticancer drugs in hospitals in NW England as well as selected studies

Drug name	Consumption for NW England hospitals shown in g/year and ($\mu\text{g}/\text{capita}/\text{d}$)						Average (range) for NW hospitals (g/yr)	International studies	
	University hospitals of Morecombe Bay ²	Lancashire teaching hospitals ³	Blackpool teaching hospitals NHS foundation ⁴	East Lancashire teaching hospitals ⁵	Greater Manchester & Cheshire cancer network ⁶	Clatterbridge centre for oncology ⁷		France, 2008 [14] (kg/yr)	University Hospital, Geneva Switzerland [64] (g/yr) ¹
Cyclophosphamide	1300 (9.8)	610 (4.3)	1900 (15.8)	1300 (7.1)	1400 (2.6)	71000 (84.5)	12918(310-71000)	310	610
Chlorambucil	12 (0.1)	-	10 (0.1)	-	12 (0.0)	-	6 (10-12)	8	-
Melphalan	1 (0.0)	-	20 (0.2)	-	1 (0.0)	-	4 (1-20)	5	-
Ifosfamide	150 (1.1)	-	-	-	120 (0.2)	1000 (1.2)	423 (120-1000)	100	450
Bendamustine	-	-	1 (0.0)	-	91 (0.2)	-	15 (1-91)	-	-
Busulfan	<1	-	30 (0.2)	-	-	-	5 (<1-30)	-	-
Treosulfan	200 (1.5)	860 (6.0)	400 (3.3)	100 (0.5)	-	-	260 (100-860)	-	-
Carmustine	-	-	6 (0.0)	-	-	-	1 (6)	2	-
Lomustine	-	-	6 (0.0)	-	-	42 (0.0)	8 (6-42)	3	-
Temozolomide	-	120 (0.8)	-	-	-	900 (1.1)	170 (120-900)	54	-
Dacarbazine	83 (0.6)	36 (0.3)	64 (0.5)	60 (0.3)	50 (0.1)	460 (0.5)	126 (36-460)	29	-
Methotrexate	12 (0.1)	-	130 (1.1)	7 (0.0)	260 (0.5)	900 (1.1)	218 (7-	75	410

							900)		
Pemetrexed	160 (1.2)	150 (1.1)	130 (1.1)	140 (0.8)	35 (0.1)	870 (1.0)	248 (35-870)	37	-
Mercaptopurine	16 (0.1)	-	26 (0.2)	-	90 (0.2)	-	22 (16-90)	95	-
Tioguanine	-	-	-	-	2 (0.0)	-	<1 (2)	2	-
Cladribine	<1	1 (0.0)	<1	-	<1	-	<1 (<1-1)	-	-
Fludarabine	11 (0.1)	-	9 (0.1)	-	16 (0.0)	-	6 (9-16)	6	6
Cytarabine	8 (0.1)	-	940 (7.8)	64 (0.4)	970 (1.8)	-	330 (8-970)	130	670
5-Fluorouracil	2500 (18.9)	3100 (21.8)	1800 (14.9)	790 (4.3)	1800 (3.4)	13000 (1.5)	3832 (790-13000)	1700	3100
Tegafur	-	58 (0.4)	-	-	-	58 (0.0)	19 (58)	37	-
Gemcitabine	1300 (9.8)	2300 (16.1)	860 (7.1)	1600 (8.8)	110 (0.2)	6800 (0.8)	2162 (110-6800)	380	660
Capecitabine	29000 (218.8)	64000 (449.3)	34000 (282.1)	-	-	230000 (27.4)	59500 (29000-230000)	5100	-
Azacitidine	18 (0.1)	-	11 (0.1)	28 (0.2)	17 (0.0)	-	12 (11-28)	-	-
Vinblastine	2 (0.0)	-	2 (0.0)	<1	1 (0.0)	-	1 (<1-2)	1	-
Vincristine	1 (0.0)	1 (0.0)	1 (0.0)	<1	1 (0.0)	<1	1 (<1-1)	<1	1
Vinorelbine	13 (0.1)	19 (0.1)	45 (0.4)	-	1 (0.0)	220 (0.0)	50 (1-220)	13	-
Etoposide	190 (1.4)	90 (0.6)	210 (1.7)	3 (0.0)	38 (0.1)	700 (0.1)	205 (3-700)	41	110
Paclitaxel	35 (0.3)	200 (1.4)	39 (0.3)	57 (0.3)	140 (0.3)	390 (0.0)	144 (35-390)	39	79
Docetaxel	58 (0.4)	74 (0.5)	44 (0.4)	53 (0.3)	43 (0.1)	260 (0.0)	89 (44-260)	27	43
Trabectedin	-	-	-	-	-	6 (0.0)	1 (6)	-	-
Dactinomycin	-	-	-	-	-	72 (0.0)	12 (72)	-	-

Doxorubicin	26 (0.2)	6 (0.0)	14 (0.1)	27 (0.1)	32 (0.1)	88 (0.0)	32 (6-88)	17	30
Daunorubicin	-	-	15 (0.1)	-	11 (0.0)	-	4 (11-15)	1	-
Epirubicin	87 (0.7)	95 (0.7)	70 (0.6)	96 (0.5)	61 (0.1)	44 (0.0)	76 (44-96)	18	41
Idarubicin	<1	-	1 (0.0)	-	1 (0.0)	-	<1 (<1-1)	<1	-
Mitoxantrone	<1	-	1 (0.0)	-	<1	-	<1 (<1-1)	<1	-
Bleomycin	1 (0.0)	4 (0.0)	2 (0.0)	<1	2 (0.0)	7 (0.0)	3 (<1 -4)	1	-
Mitomycin C	16 (0.1)	<1	11 (0.1)	13 (0.1)	3 (0.0)	<1	8 (<1-16)	3	9
Cisplatin	45 (0.3)	190 (1.3)	39 (0.3)	43 (0.2)	16 (0.0)	370 (0.0)	117 (16-370)	23	67
Carboplatin	320 (2.4)	950 (6.7)	540 (4.5)	600 (3.3)	15 (0.0)	2800 (0.3)	871 (15-2800)	84	330
Oxaliplatin	96 (0.7)	130 (0.9)	110 (0.9)	89 (0.5)	74 (0.1)	510 (0.1)	168 (74-510)	33	64
Procarbazine	24 (0.2)	-	-	-	3 (0.0)	120 (0.0)	25 (3-120)	35	-
Rituximab	-	120 (0.8)	320 (2.7)	-	310 (0.6)	18 (0.0)	128 (18-320)	72	-
Trastuzumab	250 (1.9)	370 (2.6)	160 (1.3)	260 (1.4)	-	2000 (0.2)	507 (160-2000)	56	-
Alemtuzumab	-	-	-	-	30 (0.1)	-	5 (30)	-	-
Cetuximab	17 (0.1)	110 (0.8)	57 (0.5)	-	-	270 (0.0)	76 (17-270)	55	-

“-” = not recorded

¹ Calculated using the average dose (mg) from NW hospital survey

² Comprising of Furness general hospital, Royal Lancaster Infirmary, Westmorland general hospital, Queen Victoria hospital, Ulverston community health centre. Population served 363,000

³ Comprising of Royal Preston hospital (Rosemere cancer foundation) and Chorley and South Ribble hospital. Population served 390,000

⁴ Comprising of Blackpool Victoria hospital, Clifton hospital, Fleetwood hospital and three elderly rehabilitation hospitals. Population served 330,000

⁵ Comprising of Burnley general hospital, Royal Blackburn hospital and Inpatient rehabilitation services are also provided at Pendle community hospital and the Rakehead unit at Burnley general hospital. Outpatient and diagnostic services are also provided at the Accrington Victoria, Clitheroe hospital, Rossendale and St Peters Primary health care centre's. Population served 500,000

⁶ Comprising of NHS Trafford (Trafford general hospital host to the Trafford Macmillan care centre); Bolton NHS Foundation trust (Royal Bolton hospital); Salford Royal NHS Foundation trust (Salford Royal hospital); Mid Cheshire hospitals NHS foundation trust (Leighton hospital, Victoria Infirmary and Elmhurst intermediate care centre); Wrightington, Wigan and Leigh NHS foundation trust (Royal Albert Edward Infirmary, Leigh Infirmary, Wrightington hospital and Thomas Linacre centre (provides the majority of out-patient services for the Trust). Population served 1,463,000

⁷ Comprising of outpatient clinics at Linda McCartney centre (Royal Liverpool University hospital), the Countess of Chester, Southport hospital, Halton general hospital, Aintree University hospital, Broadgreen hospital and The Liverpool Woman's. Population served 2,300,000

Table S2: Average urinary excretion rates of the unchanged parent drug

% of administered drug excreted (i.e. not metabolized)					
<5%	5-15%	15-25%	25-45%	45-75%	>75%
Chlorambucil ^{1,2,3,4} [1]	Temozolomide ^{1,2} [7, 8]	Cyclophosphamide ^{1,2,3} [12, 14-17]	Ifosfamide ^{2,3} [17, 26, 27]	Carmustine ^{e1,2}	Methotrexate ^{2,3} [29]
Busulfan ^{1,2,5} [2]	Mercaptopurine ^{1,2}	Melphalan ^{1,2} [18]	Dacarbazine ^{1,2}	Azacitidine ^{e2}	Pemetrexed ^{1,2,3} [30]
Lomustine ^{1,2}	Cytarabine ²	Bendamustine ¹	Cladribine ^{1,2}	Bleomycin ^{n1,2}	
Capecitabine ^{1,2} [3]	Gemcitabine ¹ [9]	Treosulfan [19-22]	Fludarabine ^{e1,2}	Carboplatin ^{n1,2} [8]	
Trabectedin ^{1,2} [4]	Vinblastine ² [10]	Tioguanine [23, 24]	Etoposide ^{1,2,3}	Hydroxyurea ^{1,2}	
Idarubicin ² [5]	Vincristine ² [11]	5-Fluorouracil ^{1,2} [3, 9, 12]	Daunorubicin ^{1,2} [28]	Tretinoin ^{1,2}	
Gefitinib ^{1,2}	Vinorelbine ^{1,2}	Tegafur ¹	Cisplatin ¹ [8]		
Sorafenib ^{1,2}	Paclitaxel ^{1,2}	Dactinomycin ¹	Oxaliplatin ^{1,2} [8]		
Dasatinib ¹	Docetaxel ^{1,2}	Sunitinib ^{1,2} [25]	Topotecan ^{1,2}		
Lapatinib ¹ [6]	Doxorubicin ^{1,2,3} [12]	Irinotecan ^{1,2}			
Nilotinib ^{2,5}	Epirubicin ^{1,2} [12]				
Temsirolimus ^{1,2}	Mitoxantron ^{e1,2}				
Everolimus ^{1,2}	Mitomycin ^{1,2}				
Pazopanib ^{1,2}	Procarbazine ^{e2,4}				
Bortezomib ^{**}	Imatinib ^{1,2}				
Trastuzumab ^{***}	Erlotinib ^{1,2}				
Alemtuzumab ^{b***}	Mitotane ^{1,2,4,6} [13]				
Rituximab ^{**}	Eribulin ¹				
Cetuximab ^{**}					
Bevacizumab ^{b***}					

¹ electronic Medicines Compendium (eMC) (<http://www.medicines.org.uk/EMC>)

² Product monograph

(<http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/default.htm>)

³ RxList (<http://www.rxlist.com/script/main/hp.asp>)

⁴ Drugs.com (<http://www.drugs.com/>)

⁵ Ema (<http://www.ema.europa.eu/ema/>)

⁶ToxNet (<http://toxnet.nlm.nih.gov/>)

*** No available data (Urinary excretion data was not available for six L01X anticancer drugs)

Table S3: Physiochemical properties of selected cytotoxic drugs and their classification according to the Anatomical Therapeutic Classification (ATC) system.

ATC	Drug name	pKa	Charge at pH 7.4	Weak acid/weak base	Log Kow	Log Dow at pH 7.4	Koc ⁴	BCF ⁴	Solubility in water (mg/L) at 25°C ⁴
L01AA01	Cyclophosphamide	2.84, 6.00 [31, 32]	Neutral	Acid [32]	0.63		44	3	4.00E+04
L01BC06	Capecitabine	8.8 [33]	Neutral	Acid	0.96*		8	3	8.23E+02
L01BC02	5-Fluorouracil	7.6-8.0, 13.0 [32-34]	Neutral	Acid [32]	-0.93		4	3	1.11E+04
L01XX05	Hydroxyurea	10.6*	Neutral	Acid	-1.27		3	3	7.91E+04
L01XE01	Imatinib	8.07, 3.73, 2.56, 1.52*	Positive	Base		0.19	16	3	6.48E+01
L01BA01	Methotrexate	3.80, 4.8, 5.6 [33]	Negative	Acid		-1.41	20	3	4.98E+03
L01XA02	Carboplatin	0.24, 3.55*		Base	-1.78	0.01	891 [35]		
L01BC05	Gemcitabine	3.6 [34]	Neutral	Base	-1.24		1	3	1.53E+04 ⁶
L01CB01	Etoposide	9.8 [36]	Neutral	Acid	0.60		19	3	5.87E+01
L01AA05	Ifosfamide	1.45-4.0 [31, 32]	Neutral	Base [32]	0.86		51	3	3.78E+03
L01AX04	Dacarbazine	4.42*	Neutral	Base	-0.24		15	10	4.22E+03
L01AB02	Treosulfan	12.36*	Neutral	Acid	-2.09*		1	3	7.00E+04 ⁸
L01XX23	Mitotane	N/A	Neutral	N/A	6.11*		154882	4989	1.00E-01
L01XE07	Lapatinib	3.80, 7.20 ² *	Positive	Base		4.72	426580	1127	9.06E-02
L01CD01	Paclitaxel	11.99	Neutral	Zwitterion [32]	5.25		58884	750	1.07E-04
L01AA03	Melphalan	1.83, 9.13 [37]	Neutral	Acid [38]	-0.52		14	3	2.71E+02
L01AA09	Bendamustine	0.88, 4.17, 6.94 ⁵	Negative	Zwitterion/Acid		2.84	977	3	2.69E+01
L01AD01	Carmustine	12.27*	Neutral	Acid	1.53		89	5	1.83E+03
L01AX03	Temozolomide	N/A [39]	Neutral	Base	1.15		29	3	1.81E+03
L01BA04	Pemetrexed	3.6, 4.4 [33]	Negative	Acid		-2.43	60	3	1.84E+02

L01BB02	Mercaptopurine	7.9 [40]	Neutral	Acid [40]	0.67 [40]		40	3	1.98E+04
L01BB05	Fludarabine	3.2, 5.8*	Negative	Acid		-1.22	2	3	1.44E+04
L01BC01	Cytarabine	4.2 [34]	Neutral	Base	-2.15		1	3	8.66E+04
L01BC03	Tegafur	7.98 ¹	Neutral	Acid	-0.27		6	3	3.64E+03
L01BC07	Azacitidine	2-3 [41]	Neutral	Base	-2.17		1	3	8.89E+04
L01CA04	Vinorelbine	7.4, 5.4 [42, 43]	Positive	Base	4.72*	4.57	30200	604	9.86E-03
L01CD02	Docetaxel	12.02*	Neutral	Acid	3.64*		27	65	5.17E-03
L01DA01	Dactinomycin	8.06 [44]	Neutral	Acid	1.42*				
L01DB01	Doxorubicin	7.34, 8.3, 9.46 [31, 33, 45]	Positive	Base [32]		-1.93	389	3	5.34E+02
L01DB02	Daunorubicin	8.4 [31, 45]	Positive	Base [32]		-0.14	490	1	1.23E+02
L01DB03	Epirubicin	7.7 [31]	Positive	Base*		-0.30	372	4	6.25E+02
L01DC01	Bleomycin	7.3 [46]	Positive	Base		-0.47			
L01DC03	Mitomycin C	3.2	Neutral	Base	-0.38		76	3	8.11E+03
L01XA01	Cisplatin	6.6, 5.5, 7.3 [47]			-2.40	-2.19	12589 [35]		
L01XA03	Oxaliplatin	7.35, 9.99*		Base	-1.63	-1.42			
L01XB01	Procarbazine	6.8*	Neutral	Base	-0.82*		18	3	8.32E+03
L01XE03	Erlotinib	5.42*	Neutral	Base	2.96*		2188	42	9.97E+00
L01XE04	Sunitinib	8.95*	Positive	Base		0.76	891	29	1.52E+01
L01XE05	Sorafenib	11.55, 2.03 ² *	Neutral	Base/Acid	4.39*		2884	366	2.14E-01
L01XE08	Nilotinib	2.1, 5.4 ¹	Neutral	Base	3.60		79433	110	3.90E-01
L01XE11	Pazopanib	2.1, 6.4, 10.2 ³	Neutral	Base/Acid	3.38*		12023	79	2.32E+00
L01XX14	Tretinoin	5.0*	Negative	Acid		4.30			
L01XX17	Topotecan	0.60, 6.99, 10.50 [48]	Positive	Base/Acid		-3.13	107	3	3.30E+02
L01XX19	Irinotecan	8.1*	Positive	Base		3.24	2818	355	3.64E-02
L01XX32	Bortezomib	13.82*	Neutral	Acid	1.47*		766	4	2.13E+02
L01XX41	Eribulin	9.59 ²	Positive	Base		-0.34	1288	14	2.70E+00

¹ www.ema.europa.eu/docs/en_GB/.../WC500034398.pdf

² *ACD properties calculator* (<http://www.chemicalize.org/structure>)

³ <http://www.medicines.org.au/files/gwpvotri.pdf>

⁴ BCF predicted with EPI SUITE: linear relationship with *k_{ow}* does not hold for many compounds with high polarity (see text)

⁵ <http://www.faqs.org/patents/app/20090264488>

⁶ MSDS gemcitabine (<http://ehs.lilly.com/msds/Gemzar.pdf>)

⁷ MSDS imatinib

(http://export.fass.se/pdfprint/servlet/se.itsip.pdfprint.servlets.ConvertServlet?nplId=20031111000058&docTypeId=78&userType=2¶Imported=null&orgNplId=null&showParaLink=null&hasEnvSection=yes¶Info=null&orgCompany=null&docId=ID18IILYT1XUZ1XGCS_IDX0000000180&fontSize=standard)

⁸ MSDS treosulfan (http://www.medac.de/medac_international/data/SDS/treosulfan_E.pdf)

*From predicted data

** Calculated as an average, with consideration to dastinib a similar compound to basic ionization

Table S4: Degradative loss processes: biodegradation and hydrolysis

Drug Name	Biodegradation				Hydrolysis			% STP total removal (EPI suite)	Ref.
	Test	Incubation (days)	Initial conc.	Results	Log k _{OH} (L/mole.s) ¹	% loss in 5days			
						at pH 7.0	at pH 8.1		
Cyclophosphamide	ZWT ² (OECD 302B)	28	51.7mg/L	No degradation	-8.458	Neg.	Neg.	1.86	[49]
	OECD confirmatory	10	375, 750mg/L	0±5% degradation					[50]
	CBT ³ (OECD 1992)	40	4.3mg/L	28-66% degradation in 40 days. Chemical structurally related to CP					[51]
	ZWT ² (OECD 1992)	40	200mg/L	5-72% degradation in 28 days. Chemical structurally related to CP					[51]
	AS incubation	1	90, 900ng/L	No degradation					[52]
Ifosfamide	ZWT ² (OECD 302B)	42	51.7mg/L	No degradation	-7.397	Neg.	Neg.	1.88	[53]
	STP simulation	42	11.4µg/L	Negligible					[53]

	test (OECD 1992)								
	CBT ³ (OECD 1992)	40	4.3mg/L	28-66% degradation in 40 days. Chemical structurally related to IF					[51]
	ZWT ² (OECD 1992)	40	200mg/L	5-72% degradation in 28 days. Chemical structurally related to IF					[51]
Treosulfan	CBT ³ (OECD 301D)	40	5mg/L	30% degradation in the first 28 days (40% in 40 days)	N/A	N/A	N/A	1.85	[54]
Methotrexate	OECD confirmatory (AS incubation)	10	10, 20mg/L	98±6% degradation. > 10% in the first four days	N/A	N/A	N/A	1.85	[50]
Pemetrexed	Ready biodegradability	29	N/A	20% was released as CO ²	N/A	<10% (at 50°C) ⁴	N/A	1.85	MSDS ⁴
	Biodegradation (sludge)	1	N/A	>99% disappearance when incubated with 1.5g/L					MSDS ⁴

				sludge solids. After 1 hour incubation 90% of pemetrexed had degraded					
Fludarabine	N/A	N/A	N/A	N/A	-4.097	Neg.	Neg.	1.85	N/A
Cytarabine	OECD confirmatory AS incubation	10	12.5, 25mg/L	60±8% degradation, 2 days = ~10%	N/A	N/A	N/A	1.85	[50]
	CBT ³ (OECD 301D)	40	N/A	50% degradation after 20days					[55]
	ZWT ² (OECD 302B)	40	N/A	>95% degradation HOW MANY DAYS?					[55]
5-fluorouracil	CBT ³ (OECD 301D)	28 and 40	9.02mg/L	No degradation	N/A	N/A	N/A	1.85	[55]
	ZWT ² (OECD 302B)	28	854mg/L	2% degradation					[55]
	OECD 303A confirmatory AS incubation	10	5, 10, 20mg/L	100±4% (15% after 1 day and a sharp increase to 100% on day 2) Higher degradation rate with lower concentrations					[50]
	AS incubation	50	50ug/L	<60% removal					[56]

				after 50 days					
	AS incubation	1	5, 500ug/L	Complete degradation					[57]
	ZWT ² (OECD 302B)	21	270mg/L	No degradation, using pre-adapted AS					[3]
	Inherent biodegradation test, 4g AS/L and closed test vessels	14	0.2, 11.4mg/L	97.5->100% degradation. > 25% Biodegradation in 1day					[3]
	OECD 303A	3	10mg/L	38-92% biodegradation					[3]
Gemcitabine	CBT ³ (OECD 301D)	40	1660mg/L	45% Degradation	N/A	Neg. ⁵	N/A	1.85	[55]
	ZWT ² (OECD 302B)	40	1660mg/L	50% degradation					[55]
	Aerobic biodegradation	28		30% degradation					MSDS ⁵
Capecitabine	ZWT ² (OECD 303B)	28	N/A	58% degradation (15% removed in 7 days)	N/A	N/A	N/A	1.85	[3]
	Like OECD 302C	21	30mg/L	41% mineralization, 27% mineralization in 14 days					[3]
	Like OECD	84		55-66%					[3]

	302C			mineralization, 29% mineralization in 28 days					
Vinblastine	CBT ³	28	N/A	10% Degradation	0.016/-0.835/- 1.261	0.63- 4.48	7.95- 56.40	NOT ON LIST	[58]
	ZWT ²	40	N/A	18% degradation					[58]
Vincristine	CBT ³	28	N/A	30% degradation	-0.788/0.149	0.70- 6.09	8.86- 76.60	NOT ON LIST	[58]
Vinorelbine	N/A	N/A	N/A	N/A	-0.844/0.004/- 1.261	0.24- 4.36	2.98- 54.90	66.90	N/A
Etoposide	N/A	N/A	N/A	N/A	-2.689	0.01	0.11	1.86	N/A
Paclitaxel	N/A	N/A	N/A	N/A	-0.297/- 1.669/0.000/- 0.433	0.09- 4.32	1.17- 54.40	84.19	N/A
Docetaxel	N/A	N/A	N/A	N/A	-0.317/- 1.689/- 0.452/4.667	0.00- 2.08	0.00- 26.20	16.63	N/A
Doxorubicin	AS incubation	1	2500ug/L	48-74% degradation (20- 40% recovered in sludge, 6- 12% recovered in liquid phase). Degraded mainly due to adsorption to	N/A	N/A	N/A	1.85	[57]

				sludge					
Epirubicin	CBT ³ (OECD 301D)	N/A	5mg/L	No degradation	N/A	N/A	N/A	1.85	[59]
	ZWT ² (OECD 302B)	N/A	N/A	Degraded, mainly due to adsorption to sludge					[59]
	ZWT ² (OECD 302B) CBT ³ (OECD 301D)	N/A	N/A	Eliminated in ZWT but not in CBT					[57]
Mitoxantron	CBT ³ (OECD 301D)	40	5mg/L	No degradation	N/A	N/A	N/A		[54]
Mitomycin	N/A	N/A	N/A	N/A	-2.218	0.03	0.33	1.85	N/A
Cisplatin	OECD screening test	21	0, 0.32, 1.6mg/L	0±2% Degradation	N/A	N/A	N/A	N/A	[50]
Imatinib	Aerobic, 92/69/EC (L383) C.4-C	28	N/A	9-12%; not readily biodegradable	N/A	N/A	N/A	1.85	MSDS ⁶
Topotecan	N/A	N/A	N/A	N/A	-0.986	0.45	5.62	1.85	N/A
Irinotecan	N/A	N/A	N/A	N/A	-1.127/0.000	0.32-4.32	4.06-54.40	8.33	N/A

Neg. – negligible

N/A – not available

AS – activated sludge

STP – sewage treatment plant

¹ Second order rate constant estimated using the SPARC model

(<http://archemcalc.com/sparc/test/login.cfm?CFID=250050&CFTOKEN=79322869>)

² ZWT - Zahn-Wellens Test (test for inherent biodegradability – OECD302)

³ CBT – Closed Bottle Test (OECD 301)

⁴ MSDS pemetrexed (<http://ehs.lilly.com/msds/Alimta.pdf>)

⁵ MSDS gemcitabine (<http://ehs.lilly.com/msds/Gemzar.pdf>)

⁶ MSDS imatinib

(http://export.fass.se/pdfprint/servlet/se.itsip.pdfprint.servlets.ConvertServlet?nplId=20031111000058&docTypeId=78&userType=2¶Imported=null&orgNplId=null&showParaLink=null&hasEnvSection=yes¶Info=null&orgCompany=null&docId=ID18IILYT1XUZ1XGCS_IDX0000000180&fontSize=standard)

Table S5: Consumption and predicted fate of anticancer drugs likely to be present in sewage effluent based on 2010-2012 consumption in NW England. Values assume excretion of the unchanged drug based on Table S2 (Supplementary information) and ‘best values’ for estimated removal rates in STPs.

ATC Drug	Consumption (kg/year) ¹	Consumption (µg/capita/d) ²	Excretion of original drug % ³	Influent load (µg/capita/d)	% of intact drug after STP biodegradation ⁴	Load after STP biodegradation (µg/capita/d)	Predicted effluent conc. (ng/L) ⁵	Predicted river water conc. (ng/L) ⁶	Discussion
L01AA01*** Cyclophosphamide	77.51	40	21	8.4	98.1*	8.3	41.3	4.1	- Continuous diffusive discharge ⁷ - Persistence in the environment confirmed (hospital effluents, STP wastewaters and surface waters)
L01BC06*** Capecitabine	357.00	183	3	5.4	85.0	4.6	23.1	2.3	- Pro-drug of 5-FU (may contribute to 5-FU load) - Continuous diffusive discharge ⁷ - No biodegradation studies: used a predicted biodegradation rate similar to 5-FU (85% loss) – at present this is highly uncertain.
L01BC02*** Fluorouracil	22.99	12	18	2.1	85.0	1.8	8.9	0.9	- No evidence of abiotic degradation is apparent. - 5-FU has only been detected in hospital effluents, presence in surface waters needs confirming.

L01XX05*** Hydroxyurea	64.00	33	58	18.8	5.0	0.9	4.7	0.5	<ul style="list-style-type: none"> - By far the most consumed anticancer drug⁸ - No biodegradation studies: model predictions possibly underestimate its loss, particularly when incubated with activated sludge. - Urease catalyses the hydrolysis of urea, it also catalyses the hydrolysis of HU. - Due to hydrolysis the environmental persistence of this chemical is likely to be low relative to other L01 drugs. - Presence in the environment needs confirming
L01XE01*** Imatinib	20.40	10	9	0.9	98.2*	0.9	4.6	0.5	<ul style="list-style-type: none"> - Concern for contamination of soils (if sludge is dispersed onto fields) and water phase. - Presence in the environment needs confirming
L01BA01*** Methotrexate	1.31	1	83	0.6	90.0	0.5	2.5	0.2	<ul style="list-style-type: none"> - Point discharge (Primarily used to treat inpatients and administered 7days/week). Diffusive discharge (outpatient clinics) - Consumption underestimated⁸ - Methotrexate not marked for environmental concern in other studies [ref] (removal rate of 95%), however, only 10% was removed in first four days akin to incubation time at STPs - Confirmed detection in sewage effluent at 12.9ng/L
L01XA02*** Carboplatin	5.23	3	54	1.4	30.0	0.4	2.2	0.2	<ul style="list-style-type: none"> - No other biodegradation studies are available for carboplatin and this assessment is based on the results from a pilot membrane bioreactor system [ref].
L01BC05*** Gemcitabine	12.97	7	8	0.5	70.0	0.4	1.8	0.2	<ul style="list-style-type: none"> - Persistence in the environment confirmed (hospital effluents, STP wastewaters and surface waters)
L01CB01*** Etoposide	1.23	1	43	0.3	98.1*	0.3	1.3	0.1	<ul style="list-style-type: none"> - No biodegradation data - Persistence in the environment confirmed (hospital effluents and STP wastewaters)

L01XA03 Oxaliplatin	1.01	1	40	0.2	100.0**	0.2	1.0	0.1	
L01AA06*** Ifosfamide	1.27	1	26	0.2	98.1*	0.2	0.8	0.1	- Point discharge (used to treat inpatients and administered 7days/week). Continuous diffusive discharge ⁷ - Persistence in the environment confirmed (hospital effluents and STP wastewaters and surface waters)
L01AX04*** Dacarbazine	0.75	0	36	0.1	98.2*	0.1	0.7	0.1	- 58% increased consumption from 2004 to 2008 [ref]. - No biodegradation data available - Presence in the environment needs confirming
L01AB02*** Treosulfan	1.56	1	22	0.2	70.0	0.1	0.6	0.1	- Administered at high doses (1-5g) - Expect periodic detection or detection near hospitals that utilise this specialist chemotherapy.
L01XA01 Cisplatin	0.70	0	33	0.1	98.2*	0.1	0.6	0.1	
L01XE03 Erlotinib	4.14	2	6	0.1	94.6*	0.1	0.6	0.1	
L01BC01 Cytarabine	1.98	1	10	0.1	90.0	0.1	0.5	0.0	
L01BA04 Pemetrexed	1.49	1	80	0.6	10.0	0.1	0.3	0.0	
L01XE04 Sunitinib	0.70	0	16	0.1	98.1*	0.1	0.3	0.0	
L01XX19 Irinotecan	0.56	0	16	0.0	91.7*	0.0	0.2	0.0	
L01AX03 Temozolomide	1.02	1	7	0.0	98.1*	0.0	0.2	0.0	
L01BC07 Azacitidine	0.07	0	68	0.0	98.2*	0.0	0.1	0.0	

L01DB03 Epirubicin	0.45	0	11	0.0	98.2*	0.0	0.1	0.0	
L01CD02 Docetaxel	0.53	0	7	0.0	83.4*	0.0	0.1	0.0	
L01BC03 Tegafur	0.12	0	20	0.0	98.2*	0.0	0.1	0.0	
L01DB01 Doxorubicin	0.19	0	14	0.0	80.0	0.0	0.1	0.0	
L01XX23**** Mitotane	4.50	2	6	0.1	7.4*	0.0	0.1	0.0	- High dose (2-10g/day) only used at specialist hospitals - High bioaccumulation potential (log K_{oc} > 5)
L01XE07**** Lapatinib	4.60	2	1	0.0	33.1*	0.0	0.1	0.0	- 92% of lapatinib seen in fecal excretion - High bioaccumulation potential (log K_{oc} > 5) - 116% increased consumption from 2004 to 2008 [ref].
L01AA09 Bendamustine	0.09	0	20	0.0	95.5*	0.0	0.0	0.0	
L01XB01 Procarbazine	0.15	0	11	0.0	98.2*	0.0	0.0	0.0	
L01CA04 Vinorelbine	0.30	0	13	0.0	33.1*	0.0	0.0	0.0	
L01DA01 Dactinomycin	0.07	0	17	0.0	100.0**	0.0	0.0	0.0	
L01BB05 Fludarabine	0.04	0	34	0.0	98.2*	0.0	0.0	0.0	
L01XE08 Nilotinib	0.57	0	2	0.0	84.5*	0.0	0.0	0.0	
L01DC01 Bleomycin	0.02	0	62	0.0	100.0**	0.0	0.0	0.0	
L01XX17 Topotecan	0.03	0	33	0.0	98.2*	0.0	0.0	0.0	

L01CD01**** Paclitaxel	0.86	0	7	0.0	15.8*	0.0	0.0	0.0	- 61% of paclitaxel seen in fecal excretion - High bioaccumulation potential (log K _{oc} > 5)
L01XX14 Tretinoin	0.02	0	63	0.0	54.5*	0.0	0.0	0.0	
L01DB02 Daunorubicin	0.03	0	25	0.0	98.2*	0.0	0.0	0.0	
L01XX41 Eribulin	0.06	0	9	0.0	98.2*	0.0	0.0	0.0	
L01XE05 Sorafenib	10.28	5	0	0.0	49.9*	0.0	0.0	0.0	
L01XX32 Bortezomib	0.00	0	100	0.0	98.0*	0.0	0.0	0.0	
L01DC03 Mitomycin	0.04	0	10	0.0	98.2*	0.0	0.0	0.0	
L01AA03 Melphalan	0.02	0	20	0.0	98.2*	0.0	0.0	0.0	
L01AD01 Carmustine	0.01	0	57	0.0	98.0*	0.0	0.0	0.0	
L01XE11 Pazopanib	0.05	0	4	0.0	89.4*	0.0	0.0	0.0	
L01BB02 Mitoxantrone	0.00	0	7	0.0	100.0**	0.0	0.0	0.0	

¹ Consumption total of NW survey

² Based on NW population of 5,346,000 from the populations each hospital serves

³ Mean excretion rate taken from *n* clinical studies

⁴ Estimated from EPISUITE biowin model or from biodegradation data table 4. Predictions based on literature values are shown with an asterisk. Where no EPISUITE prediction or literature value could be obtained it was presumed that 100% of the drug remained intact.

⁵ 200L/head dilution expected in STP [12]

⁶ Further 10-fold dilution in the river [12]

⁷ Communication with Blackpool Victoria hospital confirmed that treatments are more likely to commence during outpatients clinics (Mon-Fri), however, predominantly consumed by oral ingestion within the patients' own home)

⁸ Used in another ATC class


* Predicted from EPISUITE

** No rate available

*** Priority chemical in surface water

**** Priority chemical in soil

Figure S1: Box and whisker plot of log K_{ow} values for a wide number of anticancer drugs. For each chemical the K_{ow} values were obtained from the literature (i.e. empirically observed) or calculated ($n=1-22$)



Recommended log K_{ow} based on the most reliable data sources with consideration of D_{ow} for ionisable compounds

Supplementary Information References

1. Alberts, D.S., et al., *Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report*. Cancer Treatment Reviews, 1979. **6, Supplement 1(0)**: p. 9-17.
2. Hans Ehrsson , M.H., Mats Ehrnebo & Miloslav Beran *Busulfan kinetics*. Clinical Pharmacology & Therapeutics, 1983. **34(1)**: p. 86-89.
3. Straub, J.O., *Combined environmental risk assessment for 5-fluorouracil and capecitabine in Europe*. Integrated Environmental Assessment and Management, 2010. **6(S1)**: p. 540-566.
4. Beumer, J.H., et al., *Trabectedin (YondelisTM; formerly ET-743), a mass balance study in patients with advanced cancer*. Investigational New Drugs, 2005. **23(5)**: p. 429-436.
5. Lu K, S.N., Kavanagh J, Feun LG, Burgess M, Bodey GP, Loo TL., *Clinical pharmacology of 4-demethoxydaunorubicin (DMDR)*. Cancer Chemotherapy Pharmacology, 1986. **17(2)**: p. 143-8.
6. Castellino, S., et al., *Human Metabolism of Lapatinib, a Dual Kinase Inhibitor: Implications for Hepatotoxicity*. Drug Metabolism and Disposition, 2011.
7. Baker, S.D., et al., *Absorption, Metabolism, and Excretion of 14C-Temozolomide following Oral Administration to Patients with Advanced Cancer*. Clinical Cancer Research, 1999. **5(2)**: p. 309-317.
8. Rowney, N.C., A.C. Johnson, and R.J. Williams, *Cytotoxic drugs in drinking water: A prediction and risk assessment exercise for the thames catchment in the United Kingdom*. Environmental Toxicology and Chemistry, 2009. **28(12)**: p. 2733-2743.
9. Weissbrodt, D., et al., *Mass Flows of X-ray Contrast Media and Cytostatics in Hospital Wastewater*. Environmental Science & Technology, 2009. **43(13)**: p. 4810-4817.
10. Olaf Tellingén, J.H.B., Willem J. Nooijen and Auke Bult, *Tissue disposition, excretion and metabolism of vinblastine in mice as determined by high-performance liquid chromatography* Cancer Chemotherapy and Pharmacology, 1993. **32(4)**: p. 286-292.
11. Bedikian, A.Y., et al., *Pharmacokinetics and Urinary Excretion of Vincristine Sulfate Liposomes Injection in Metastatic Melanoma Patients*. The Journal of Clinical Pharmacology, 2006. **46(7)**: p. 727-737.
12. Johnson, A.C., et al., *Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study*. Journal of Hydrology, 2008. **348(1-2)**: p. 167-175.
13. Edward Chu; Vincent T DeVita, J., *Physician's cancer chemotherapy drug manual 2007* 2007: Sudbury, MA : Jones and Bartlett.
14. Joqueviel, C., et al., *Urinary Excretion of Cyclophosphamide in Humans, Determined by Phosphorus-31 Nuclear Magnetic Resonance Spectroscopy*. Drug Metabolism and Disposition, 1998. **26(5)**: p. 418-428.
15. Hadidi, A.-H.F.A., C.E.A. Coulter, and J.R. Idle, *Phenotypically Deficient Urinary Elimination of Carboxyphosphamide after Cyclophosphamide Administration to Cancer Patients*. Cancer Research, 1988. **48(18)**: p. 5167-5171.

16. McCune, J.S., et al., *Population Pharmacokinetics of Cyclophosphamide and Metabolites in Children With Neuroblastoma: A Report From the Children's Oncology Group*. The Journal of Clinical Pharmacology, 2008.
17. Angela S Ensslin, Y.S., Angelika Pethran, Andreas Pfaller, Horst Rommelt, Gunter Fruhmann, *Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs*. Occupational and Environmental Medicine, 1994. **51**: p. 229-233.
18. Nath, C.E., et al., *Melphalan pharmacokinetics in children with malignant disease: influence of body weight, renal function, carboplatin therapy and total body irradiation*. British Journal of Clinical Pharmacology, 2005. **59**(3): p. 314-324.
19. Hilger, R.A., et al., *Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer*. Cancer Chemotherapy and Pharmacology, 2000. **45**(6): p. 483-488.
20. Hilger, R.A., et al., *Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors*. Cancer Chemotherapy and Pharmacology, 1998. **42**(2): p. 99-104.
21. S. Feyerabend, G.F., J. Krug, A. Kassen and A. Stenzl, *Cytotoxic effects of treosulfan on prostate cancer cell lines*. . Anticancer Reseach, 2007. **27**: p. 2403-2408.
22. Scheulen, M.E., et al., *Clinical Phase I Dose Escalation and Pharmacokinetic Study of High-Dose Chemotherapy with Treosulfan and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Advanced Malignancies*. Clinical Cancer Research, 2000. **6**(11): p. 4209-4216.
23. LePage, G.A. and J.P. Whitecar, *Pharmacology of 6-Thioguanine in Man*. Cancer Research, 1971. **31**(11): p. 1627-1631.
24. Estelle R. Lefkowitz, W.A.C., Paul Calabresi, et al., *Clinical and Pharmacologic Effects of Combinations of 6-Thioguanine and Duazomycin A in Patients with Neoplastic Disease*. Cancer Research, 1965. **25**: p. 1207-1212.
25. Houk, B.E., et al., *A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients*. Clinical Cancer Research, 2009. **15**(7): p. 2497-2506.
26. Kurowski V, W.T., *Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy*. Cancer Chemotherapy and Pharmacology, 1997. **39**(5): p. 431-9.
27. V Gilard, M.C.M.-M., M De Forni, U Niemeyer, J C Ader, R Martino, *Determination of the urinary excretion of ifosfamide and its phosphorylated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy*. Cancer Chemotherapy and Pharmacology, 1993. **31**(5): p. 387-394.
28. Catapano CV, G.A., Broggin M, Corada M, Bartosek I, Italia C, Donelli MG., *Hepatobiliary metabolism and urinary excretion of 4-demethoxydaunorubicin as compared to daunorubicin in rats*. Anticancer Reseach, 1988. **8**(4): p. 725-31.
29. Blum, R., J.F. Seymour, and G. Toner, *Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment*. Annals of Oncology, 2002. **13**(2): p. 327-330.
30. Sweeney, C.J., et al., *Two Drug Interaction Studies Evaluating the Pharmacokinetics and Toxicity of Pemetrexed When Coadministered with*

- Aspirin or Ibuprofen in Patients with Advanced Cancer*. Clinical Cancer Research, 2006. **12**(2): p. 536-542.
31. Sottani, C., et al., *Simultaneous determination of cyclophosphamide, ifosfamide, doxorubicin, epirubicin and daunorubicin in human urine using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry: bioanalytical method validation*. Rapid Communications in Mass Spectrometry, 2008. **22**(17): p. 2645-2659.
 32. Mahoney, B.P., et al., *Tumor acidity, ion trapping and chemotherapeutics: I. Acid pH affects the distribution of chemotherapeutic agents in vitro*. Biochemical Pharmacology, 2003. **66**(7): p. 1207-1218.
 33. *The hazardous substances databank*, TOXNET.
 34. Kovalova, L., C.S. McArdell, and J. Hollender, *Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry*. Journal of Chromatography A, 2009. **1216**(7): p. 1100-1108.
 35. Lenz, K., et al., *Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents*. Chemosphere, 2007. **69**(11): p. 1765-1774.
 36. Weylandt, K.H., et al., *ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment*. Molecular Cancer Therapeutics, 2007. **6**(3): p. 979-986.
 37. Wu, Z.-Y., B.M. Smithers, and M.S. Roberts, *Tissue and Perfusate Pharmacokinetics of Melphalan in Isolated Perfused Rat Hindlimb*. Journal of Pharmacology and Experimental Therapeutics, 1997. **282**(3): p. 1131-1138.
 38. Tannock, V.V.a.I.F., *Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan*. Br J Cancer, 1997. **75**(8): p. 1167-1172.
 39. *Assessment report for temomedac*, 2010: London.
 40. Deguchi, Y., et al., *Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier I*. Life Sciences, 2000. **66**(7): p. 649-662.
 41. Marin, D., C. Teijeiro, and J.J. Piña, *Electrochemical behaviour and micromolar determination of the antineoplastic agent 5-azacytidine and its mixtures with the nucleoside cytidine*. Journal of Electroanalytical Chemistry, 1996. **407**(1-2): p. 189-194.
 42. Mouchard-Delmas, C., B. Gourdiere, and R. Vistelle, *Determination of vinorelbine in rabbit plasma by high-performance liquid chromatography with coulometric detection*. Journal of Chromatography B: Biomedical Sciences and Applications, 1995. **663**(2): p. 390-394.
 43. Owellen, R.J., et al., *Correlation of biologic data with physico-chemical properties among the Vinca alkaloids and their congeners*. Biochemical Pharmacology, 1977. **26**(13): p. 1213-1219.
 44. Vives, M., et al., *Spectroscopic study of the interaction of actinomycin D with oligonucleotides carrying the central base sequences -XGCY- and -XGGCCY- using multivariate methods*. Analytical and Bioanalytical Chemistry, 2007. **387**(1): p. 311-320.
 45. Gallois, L., M. Fiallo, and A. Garnier-Suillerot, *Comparison of the interaction of doxorubicin, daunorubicin, idarubicin and idarubicinol with large unilamellar vesicles: Circular dichroism study*. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1998. **1370**(1): p. 31-40.

46. Kimura, E., et al., *pH-dependent coordination mode of new bleomycin synthetic analogs with copper(II), iron(II), and zinc(II)*. *Inorganic Chemistry*, 1992. **31**(21): p. 4314-4321.
47. Zimmermann, T., J. Leszczynski, and J. Burda, *Activation of the cisplatin and transplatin complexes in solution with constant pH and concentration of chloride anions; quantum chemical study*. *Journal of Molecular Modeling*, 2011: p. 1-9.
48. Rosing, H., et al., *High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma*. *Journal of Chromatography B: Biomedical Sciences and Applications*, 1995. **668**(1): p. 107-115.
49. Steger-Hartmann, T., K. Kümmerer, and A. Hartmann, *Biological Degradation of Cyclophosphamide and Its Occurrence in Sewage Water*. *Ecotoxicology and Environmental Safety*, 1997. **36**(2): p. 174-179.
50. Kiffmeyer, T., et al., *Trace enrichment, chromatographic separation and biodegradation of cytostatic compounds in surface water*. *Fresenius' Journal of Analytical Chemistry*, 1998. **361**(2): p. 185-191.
51. Kümmerer, K., et al., *Biodegradability of antineoplastic compounds in screening tests: influence of glucosidation and of stereochemistry*. *Chemosphere*, 2000. **40**(7): p. 767-773.
52. Buerge, I.J., et al., *Occurrence and Fate of the Cytostatic Drugs Cyclophosphamide and Ifosfamide in Wastewater and Surface Waters†*. *Environmental Science & Technology*, 2006. **40**(23): p. 7242-7250.
53. Kümmerer, K., T. Steger-Hartmann, and M. Meyer, *Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage*. *Water Research*, 1997. **31**(11): p. 2705-2710.
54. AlAhmad, A., K. Kummerer, and G. Schon, *Biodegradation and toxicity of the antineoplastics mitoxantron hydrochloride and treosulfane in the closed bottle test (OECD 301 D)*. *Bulletin of Environmental Contamination and Toxicology*, 1997. **58**(5): p. 704-711.
55. Kummerer, K. and A. Al-Ahmad, *Biodegradability of the anti-tumour agents 5-fluorouracil, cytarabine, and gemcitabine: Impact of the chemical structure and synergistic toxicity with hospital effluent*. *Acta hydrochimica et hydrobiologica*, 1997. **25**(4): p. 166-172.
56. Yu, J.T., E.J. Bouwer, and M. Coelhan, *Occurrence and biodegradability studies of selected pharmaceuticals and personal care products in sewage effluent*. *Agricultural Water Management*, 2006. **86**(1-2): p. 72-80.
57. Mahnik, S.N., et al., *Fate of 5-fluorouracil, doxorubicin, epirubicin, and daunorubicin in hospital wastewater and their elimination by activated sludge and treatment in a membrane-bio-reactor system*. *Chemosphere*, 2007. **66**(1): p. 30-37.
58. Al-Ahmad, A. and K. Kummerer, *Biodegradation of the antineoplastics vindesine, vincristine, and vinblastine and their toxicity against bacteria in the aquatic environment*. *Cancer Detection and Prevention*, 2001. **25**(1): p. 102-107.
59. Mahnik, S.N., et al., *Development of an analytical method for the determination of anthracyclines in hospital effluents*. *Chemosphere*, 2006. **65**(8): p. 1419-1425.